WO2022038479 - TRANSDERMAL PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS
National phase entry:
Publication Number
WO/2022/038479
Publication Date
24.02.2022
International Application No.
PCT/IB2021/057483
International Filing Date
13.08.2021
Title **
[English]
TRANSDERMAL PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS
[French]
FORMULATIONS PHARMACEUTIQUES TRANSDERMIQUES DE CANNABINOÏDES
Applicants **
PIKE THERAPEUTICS, INC.
20th Floor
250 Howe Street
Vancouver, British Columbia V6C 3R8, CA
Inventors
PLAKOGIANNIS, Fotios M.
157-14 Cryders Lane
Whitestone, New York 11357, US
MODI, Nisarg
32 Logan Avenue
1st Floor
Jersey City, New Jersey 07306, US
Priority Data
63/066,386
17.08.2020
US
63/229,021
03.08.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CIPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3057 | |
| EPO | Filing, Examination | 36941 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 15510 |
Total: 56704 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates to the transdermal administration of nabilone and cannabinoids and derivatives of these compounds, for the treatment and/or prevention and/or control of medical conditions.[French]
La présente divulgation concerne l'administration transdermique de nabilone et de cannabinoïdes et de dérivés de ces composés, pour le traitement et/ou la prévention et/ou le contrôle d'états médicaux.